Cargando…

Development of SARS-CoV-2 specific IgG and IgA antibodies in serum and milk with different SARS-COV-2 vaccines in lactating women

BACKGROUND: Our main objective was to determine the evolution of IgG and IgA antibodies directed against SARS-CoV-2 protein S in the blood of lactating women and in breast milk. METHODS: A cohort of 110 uninfected and vaccinated breastfeeding women was followed-up for 6 months at the Marqués de Vald...

Descripción completa

Detalles Bibliográficos
Autores principales: Lechosa-Muñiz, Carolina, Paz-Zulueta, María, Irure-Ventura, Juan, Mendez-Legaza, Jose Manuel, Cuesta González, Rocío, Gómez-Acebo, Inés, López-Hoyos, Marcos, Llorca, Javier, Cabero-Pérez, María Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831888/
https://www.ncbi.nlm.nih.gov/pubmed/36627706
http://dx.doi.org/10.1186/s13006-022-00536-y
_version_ 1784867944714469376
author Lechosa-Muñiz, Carolina
Paz-Zulueta, María
Irure-Ventura, Juan
Mendez-Legaza, Jose Manuel
Cuesta González, Rocío
Gómez-Acebo, Inés
López-Hoyos, Marcos
Llorca, Javier
Cabero-Pérez, María Jesús
author_facet Lechosa-Muñiz, Carolina
Paz-Zulueta, María
Irure-Ventura, Juan
Mendez-Legaza, Jose Manuel
Cuesta González, Rocío
Gómez-Acebo, Inés
López-Hoyos, Marcos
Llorca, Javier
Cabero-Pérez, María Jesús
author_sort Lechosa-Muñiz, Carolina
collection PubMed
description BACKGROUND: Our main objective was to determine the evolution of IgG and IgA antibodies directed against SARS-CoV-2 protein S in the blood of lactating women and in breast milk. METHODS: A cohort of 110 uninfected and vaccinated breastfeeding women was followed-up for 6 months at the Marqués de Valdecilla University Hospital, Spain, in 2020. An additional group of 23 breastfeeding mothers who had no previously documented infection and had not been vaccinated against SARS-CoV-2 were included as a control group. The antibodies in blood and breast milk and their evolution at 6 months post-vaccination were analysed. RESULTS: One hundred ten breastfeeding mothers were included; 70 women (63.6%) were vaccinated with two doses of BNT162b2, 20 women (18.2%) received two doses of mRNA-1273, and 20 women (18.2%) received a single dose of ChAdOx1-S. No evidence of differences between concentrations of antibodies was found according to the type of vaccine, with the exception of serum IgA antibodies, which was higher in women vaccinated with mRNA-1273: mean [95%CI]: 0.05 AU/mL [0.03,0.06] with mRNA-1273, 0.02 AU/mL [0.01,0.03] with BNT162b2 and 0.01 AU/mL [0.00,0.03] with ChAdOx1-S, ANOVA p value = 0.03. The lack of difference between vaccines was also found when anti-S1 specific IgG in serum and breast milk were measured. CONCLUSIONS: In lactating women vaccinated against COVID-19, anti-SARS-CoV-2 antibodies can be detected in both serum and breastmilk 6 months after receiving the second dose, although their concentrations decreased when compared with concentrations reached immediately after vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13006-022-00536-y.
format Online
Article
Text
id pubmed-9831888
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98318882023-01-11 Development of SARS-CoV-2 specific IgG and IgA antibodies in serum and milk with different SARS-COV-2 vaccines in lactating women Lechosa-Muñiz, Carolina Paz-Zulueta, María Irure-Ventura, Juan Mendez-Legaza, Jose Manuel Cuesta González, Rocío Gómez-Acebo, Inés López-Hoyos, Marcos Llorca, Javier Cabero-Pérez, María Jesús Int Breastfeed J Research BACKGROUND: Our main objective was to determine the evolution of IgG and IgA antibodies directed against SARS-CoV-2 protein S in the blood of lactating women and in breast milk. METHODS: A cohort of 110 uninfected and vaccinated breastfeeding women was followed-up for 6 months at the Marqués de Valdecilla University Hospital, Spain, in 2020. An additional group of 23 breastfeeding mothers who had no previously documented infection and had not been vaccinated against SARS-CoV-2 were included as a control group. The antibodies in blood and breast milk and their evolution at 6 months post-vaccination were analysed. RESULTS: One hundred ten breastfeeding mothers were included; 70 women (63.6%) were vaccinated with two doses of BNT162b2, 20 women (18.2%) received two doses of mRNA-1273, and 20 women (18.2%) received a single dose of ChAdOx1-S. No evidence of differences between concentrations of antibodies was found according to the type of vaccine, with the exception of serum IgA antibodies, which was higher in women vaccinated with mRNA-1273: mean [95%CI]: 0.05 AU/mL [0.03,0.06] with mRNA-1273, 0.02 AU/mL [0.01,0.03] with BNT162b2 and 0.01 AU/mL [0.00,0.03] with ChAdOx1-S, ANOVA p value = 0.03. The lack of difference between vaccines was also found when anti-S1 specific IgG in serum and breast milk were measured. CONCLUSIONS: In lactating women vaccinated against COVID-19, anti-SARS-CoV-2 antibodies can be detected in both serum and breastmilk 6 months after receiving the second dose, although their concentrations decreased when compared with concentrations reached immediately after vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13006-022-00536-y. BioMed Central 2023-01-11 /pmc/articles/PMC9831888/ /pubmed/36627706 http://dx.doi.org/10.1186/s13006-022-00536-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lechosa-Muñiz, Carolina
Paz-Zulueta, María
Irure-Ventura, Juan
Mendez-Legaza, Jose Manuel
Cuesta González, Rocío
Gómez-Acebo, Inés
López-Hoyos, Marcos
Llorca, Javier
Cabero-Pérez, María Jesús
Development of SARS-CoV-2 specific IgG and IgA antibodies in serum and milk with different SARS-COV-2 vaccines in lactating women
title Development of SARS-CoV-2 specific IgG and IgA antibodies in serum and milk with different SARS-COV-2 vaccines in lactating women
title_full Development of SARS-CoV-2 specific IgG and IgA antibodies in serum and milk with different SARS-COV-2 vaccines in lactating women
title_fullStr Development of SARS-CoV-2 specific IgG and IgA antibodies in serum and milk with different SARS-COV-2 vaccines in lactating women
title_full_unstemmed Development of SARS-CoV-2 specific IgG and IgA antibodies in serum and milk with different SARS-COV-2 vaccines in lactating women
title_short Development of SARS-CoV-2 specific IgG and IgA antibodies in serum and milk with different SARS-COV-2 vaccines in lactating women
title_sort development of sars-cov-2 specific igg and iga antibodies in serum and milk with different sars-cov-2 vaccines in lactating women
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831888/
https://www.ncbi.nlm.nih.gov/pubmed/36627706
http://dx.doi.org/10.1186/s13006-022-00536-y
work_keys_str_mv AT lechosamunizcarolina developmentofsarscov2specificiggandigaantibodiesinserumandmilkwithdifferentsarscov2vaccinesinlactatingwomen
AT pazzuluetamaria developmentofsarscov2specificiggandigaantibodiesinserumandmilkwithdifferentsarscov2vaccinesinlactatingwomen
AT irureventurajuan developmentofsarscov2specificiggandigaantibodiesinserumandmilkwithdifferentsarscov2vaccinesinlactatingwomen
AT mendezlegazajosemanuel developmentofsarscov2specificiggandigaantibodiesinserumandmilkwithdifferentsarscov2vaccinesinlactatingwomen
AT cuestagonzalezrocio developmentofsarscov2specificiggandigaantibodiesinserumandmilkwithdifferentsarscov2vaccinesinlactatingwomen
AT gomezaceboines developmentofsarscov2specificiggandigaantibodiesinserumandmilkwithdifferentsarscov2vaccinesinlactatingwomen
AT lopezhoyosmarcos developmentofsarscov2specificiggandigaantibodiesinserumandmilkwithdifferentsarscov2vaccinesinlactatingwomen
AT llorcajavier developmentofsarscov2specificiggandigaantibodiesinserumandmilkwithdifferentsarscov2vaccinesinlactatingwomen
AT caberoperezmariajesus developmentofsarscov2specificiggandigaantibodiesinserumandmilkwithdifferentsarscov2vaccinesinlactatingwomen